{"id":"NCT02229396","sponsor":"AstraZeneca","briefTitle":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","officialTitle":"A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-04","primaryCompletion":"2016-04-26","completion":"2017-12-28","firstPosted":"2014-09-01","resultsPosted":"2017-09-08","lastUpdate":"2018-12-31"},"enrollment":695,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Exantide with Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Exentide","otherNames":[]},{"type":"DRUG","name":"Dapagliflozin","otherNames":[]}],"arms":[{"label":"Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg","type":"EXPERIMENTAL"},{"label":"Exenatide Once Weekly 2 mg Alone","type":"EXPERIMENTAL"},{"label":"Dapagliflozin Once Daily 10 mg Alone","type":"ACTIVE_COMPARATOR"}],"summary":"Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg once daily (QD) compared to EQW 2 mg alone and dapagliflozin 10 mg QD alone in patients with Type 2 diabetes who have inadequate glycemic control on metformin.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 28","timeFrame":"Baseline to Week 28","effectByArm":[{"arm":"Dapagliflozin + Placebo","deltaMin":-1.39,"sd":null},{"arm":"Exenatide + Dapagliflozin","deltaMin":-1.98,"sd":null},{"arm":"Exenatide + Placebo","deltaMin":-1.6,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.003"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":133,"countries":["United States","Hungary","Poland","Romania","Slovakia","South Africa"]},"refs":{"pmids":["32816874","32306296","30082326","27651331"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3057&filename=d5553c00003_revised_csp_3_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":233},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Nausea","Injection site nodule","Diarrhoea"]}}